Onderneming NGM Biopharmaceuticals, Inc.
Aandelen
NGM
US62921N1054
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,54 USD | -1,28% | 0,00% | +79,28% |
Vakgebied
Aantal werknemers: 138
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 02-03-15 |
William Rieflin
CHM | Chairman | 64 | 01-09-10 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-08 |
William Chang
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-19 |
Hsiao Lieu
CTO | Chief Tech/Sci/R&D Officer | 53 | 01-03-19 |
Valerie Pierce
CMP | Compliance Officer | 61 | 29-10-19 |
David Goeddel
BRD | Director/Board Member | 72 | 01-01-08 |
Joyce Q. Acbay
LAW | General Counsel | - | 01-04-20 |
Irene Perlich
AUD | Comptroller/Controller/Auditor | - | 01-03-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 08-06-21 |
David Goeddel
BRD | Director/Board Member | 72 | 01-01-08 |
William Rieflin
CHM | Chairman | 64 | 01-09-10 |
David Woodhouse
CEO | Chief Executive Officer | 54 | 02-03-15 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 83 462 408 | 81 886 322 ( 98,11 %) | 0 | 98,11 % |
Bedrijfsgegevens
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
94080-7014, South San Francisco
+650 243 5555
http://www.ngmbio.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+79,28% | 129 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,73 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |